ArticleCurrent medical imaging2026
BrainYOLO-MCA: An Improved YOLOv11 with Multi-Scale Channel Attention for Brain Tumor Detection.
Article in Current medical imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionBrain tumor detection in magnetic resonance imaging is crucial for early diagnosis and clinical treatment planning; however, it remains a challenging task due to the difficulty in detecting tumors with blurred boundaries, high visual similarity to normal brain tissue, and tiny early-stage lesions. To address these limitations, this study proposes a novel brain tumor detection framework named BrainYOLO-MCA.
methodsBrainYOLO-MCA is an improved YOLOv11 architecture with a core design of a novel Multi-scale Channel Attention (MCA) mechanism to enhance multi-scale feature representation and fuse critical texture and background information, thereby improving the recognition of indistinct tumor boundaries. On this basis, three targeted optimizations were integrated: a dynamic upsampling strategy (DySample) to preserve the spatial details of tiny lesions, an additional small-object detection head to enhance sensitivity to early-stage small tumors, and a sparse self-attention mechanism to strengthen global contextual feature representation. The proposed model is comprehensively validated on three public brain tumor datasets (Br35H, MBrT, Figshare).
resultsExperimental results show that the study's method achieves 98.6% precision and 97.5% mAP50 on Br35H, 95.3% precision and 97.5% mAP50 on MBrT, and 96.1% precision and 96.3% mAP50 on Figshare, outperforming mainstream YOLO-based models including the baseline YOLOv11, while maintaining a lightweight architecture with only 3.1M parameters. DISCUSSION: These results demonstrate that the proposed model improves the detection of tumors with blurred boundaries and tiny lesions, while achieving consistent performance across multiple datasets. The Multi-scale Channel Attention and feature fusion strategies enhance feature representation and improve robustness and detection accuracy.
conclusionThe proposed BrainYOLO-MCA enables more accurate and reliable brain tumor detection, which can support clinical decision-making and facilitate early diagnosis of brain tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.